Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-03-12 Major Shareholding Noti…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for 'Nordnet AB (publ)' in 'SynAct Pharma AB'. It explicitly states the 'Reason for major shareholding notification' and provides the 'Before the transaction' and 'After the transaction' figures, including the new total shares (1,782,146) and the resulting percentage (5.01011 %). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2024-03-12 English
SynAct Pharma meddelar utfall av den oberoende granskningen av den kliniska 4 veckors-studien RESOLVE fas 2a i reumatoid artrit
Legal Proceedings Report Classification · 99% confidence The document is a press release titled "SynAct Pharma meddelar utfall av den oberoende granskningen av den kliniska 4 veckors-studien RESOLVE fas 2a i reumatoid artrit" (SynAct Pharma announces outcome of the independent review of the clinical 4-week study RESOLVE phase 2a in rheumatoid arthritis). It details the findings, safety data, efficacy analysis issues (placebo effect, patient heterogeneity), and the resulting decision to postpone Phase 2b trials. The text concludes with contact information and a statement indicating the information is made public under EU Market Abuse Regulation, followed by links to an attached PDF. This structure strongly suggests an official announcement of clinical trial results and subsequent strategic decisions, which falls under the scope of an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category. Since it is a specific announcement about clinical trial outcomes and strategic delays, and not a full financial report (10-K/IR) or a general transcript (CT), it is best classified as a general Regulatory Filing (RNS) as it is a mandatory disclosure of material information, or potentially an Earnings Release (ER) if the company treats clinical updates as part of its periodic reporting cycle. Given the focus on clinical trial results and strategic next steps rather than standard quarterly financial metrics, RNS is the most appropriate general regulatory disclosure category, as it is a material event disclosure. However, since the document is a detailed announcement of clinical trial results and strategic implications, and not just a brief notice that a report is attached (which would be RPA), it is a substantive disclosure. In many contexts, detailed clinical updates are often released via the same channels as Earnings Releases (ER) or are considered material news falling under RNS. Given the options, RNS serves as the best fit for a material, non-standard regulatory announcement not covered by other specific codes like DIV, CAP, or MANG.
2024-03-10 Swedish
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
Legal Proceedings Report Classification · 99% confidence The document is an announcement titled "SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis." It details the findings of an independent audit concerning a clinical trial, including safety data adjustments, efficacy observations (high placebo effect), and the decision to postpone Phase 2b development. This content relates to the results and analysis of clinical testing, which falls under the scope of an Audit Report / Information (AR), as it is a standalone report detailing audit results and applied accounting/analysis principles for a specific study, distinct from a full Annual Report (10-K) or a general Earnings Release (ER). Crucially, the document ends with a statement: "This information is information that SynAct Pharma is obliged to make public pursuant to the EU Market Abuse Regulation," and lists attachments, suggesting it is a formal regulatory disclosure. Since it focuses heavily on the audit results and subsequent impact on future trials, AR is the most appropriate classification over a general RNS.
2024-03-10 English
Marina Bozilenko avgår som styrelseledamot i SynAct Pharma
Board/Management Information Classification · 100% confidence The document text is a short announcement in Swedish stating that Marina Bozilenko is resigning from her position as a board member ('styrelseledamot') of SynAct Pharma due to personal reasons. This directly concerns a change in the company's board of directors or senior management. According to the definitions, this corresponds to 'Board/Management Information' (Code: MANG). The document length is short (1741 chars), but it is the primary announcement itself, not an announcement *about* a report, so RPA/RNS is not the primary fit.
2024-02-27 Swedish
Marina Bozilenko resigns from Board of Directors of SynAct Pharma
Board/Management Information Classification · 100% confidence The document explicitly announces the resignation of Marina Bozilenko from the Board of Directors of SynAct Pharma. This type of announcement, detailing changes in senior management or the board, directly corresponds to the definition of 'Board/Management Information'. The filing type code for this is MANG. The document is short and contains the core announcement, confirming it is the primary filing, not an announcement of a report.
2024-02-27 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for SynAct Pharma AB covering the period January-December 2023. It contains comprehensive financial statements (income statement, balance sheet, cash flow), management commentary (VD-ord), and detailed financial analysis. It is a formal interim/annual financial report rather than just an earnings release or a simple announcement. Therefore, it is classified as an Interim/Quarterly Report (IR). Q4 2023
2024-02-23 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.